|Bid||11.00 x 900|
|Ask||15.00 x 1100|
|Day's Range||14.17 - 14.56|
|52 Week Range||11.02 - 29.29|
|Beta (3Y Monthly)||2.28|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.00|
XOMA Corporation (XOMA) announced today it has received a $5.5 million payment from Rezolute, Inc., related to the Companies’ 2017 license agreement, as most recently amended on January 7, 2019. “Our business model is fundamentally designed to generate significant long-term royalty-based revenue as the underlying assets are commercialized. Moreover, many of our license agreements include the potential for XOMA to receive significant milestone payments as the licensed assets progress. The receipt of this milestone payment is a good example of XOMA further strengthening its balance sheet with additional non-dilutive capital. This capital can be deployed to further expand our portfolio of assets from which we have the potential to earn future milestone payments and royalties,” commented Jim Neal, Chief Executive Officer at XOMA.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! We've lost count of how many times Read More...
EMERYVILLE, Calif., Jan. 03, 2019 -- XOMA Corporation (NASDAQ: XOMA) announced today Barbara Kosacz, a Partner at Cooley LLP, has joined the Company’s Board of Directors. Ms..
The Rights Offering was made pursuant to the Company’s effective shelf registration statement on file with the Securities and Exchange Commission (“SEC”) and a prospectus supplement and accompanying prospectus filed with the SEC on November 19, 2018. XOMA has engaged D.F. King & Co., Inc., to act as information agent with respect to the Rights Offering. For questions regarding the Rights Offering, or to obtain copies of the Rights Offering prospectus and any related materials, please contact D.F. King & Co. at firstname.lastname@example.org or by telephone at +1 866-721-1324.
Xoma (XOMA) delivered earnings and revenue surprises of -44.74% and 7.95%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Emeryville, California-based company said it had a loss of 55 cents. The drug developer posted revenue of $896,000 in the period. Xoma shares have declined 65 percent since the ...
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A look at the shareholders of XOMA Corporation (NASDAQ:XOMA) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insidersRead More...
Xoma (XOMA) delivered earnings and revenue surprises of -15.00% and -50.60%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Emeryville, California-based company said it had a loss of 23 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...